Andrés Cervantes is Professor of Medicine at the University of Valencia, Spain. He completed his training in Medical Oncology at the University Hospital in Valencia, one of the leading centres in Spain in promoting and training in Medical Oncology since 1980. After completing his clinical training he got a research fellowship for two years at the Free University Hospital in Amsterdam, where he obtained his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab of this institution under the mentorship of Prof. Bob Pinedo.

Dr. Cervantes serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain. He is also scientific director of the Institute of Health Research INCLIVA, one of the nationally accredited research institutes in Spain. Clinical Medicine and teaching are his main passions. His main areas of research and clinical interest are gastrointestinal and gynaecologic malignancies as well as phase I and early clinical trials and new drug development. He is a dedicated clinical investigator for rectal cancer, a topic in which he has developed several publications concerning the quality of the multidisciplinary teamwork as well as quality assessment of mesorectal surgery, how to improve on the optimal selection of initial therapy and specifically how to approach upper third rectal cancer. He is also responsible for a translational research lab, mainly working in liquid biopsies and in the molecular classification of gastrointestinal malignancies, as well as in the mechanisms of resistance for HER2 blockade in gastroesophageal adenocarcinomas. He is leading a EU granted project on gastric cancer including EU and Latin American countries to foster international cooperation and technology transfer in molecular studies for gastric cancer (LEGACY). He is the author of more than three hundred research articles and educational papers published in peer-reviewed journals. He is also one of the Editors in Chief of Cancer Treatment Reviews.

Dr. Cervantes is currently President (2023-2024​) of the European Society for Medical Oncology (ESMO). He has been serving ESMO in different working groups and committees since 2000. He started as a member of the Educational Committee, Chairing the Continuing Medical Education and E-Learning Working Group. He went on to become the Subject Editor for gastrointestinal cancer in the ESMO Clinical Practice Guidelines, becoming Chair of the Guidelines Committee thereafter. In 2014, he was the Scientific Chair of the ESMO Congress in Copenhagen. He was the Chair of the Educational Committee and Transitional Director of Education and has a seat on the ESMO Council and Executive Board. Since January 2014, he is an Associate Editor for Gastrointestinal Cancer in Annals of Oncology. He also Chairs ESMO preceptorships in colorectal and gastric cancer and the ESMO Summit in South Africa, Russia and Latin America.